Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule.

Journal of clinical pharmacy and therapeutics - 1 Apr 2020

Chen Xiao, Wang Dongdong, Xu Hong, Li Zhiping

Abstract excerpt

WHAT IS KNOWN AND OBJECTIVES: Tacrolimus, an immunosuppressant, has been used to treat paediatric systemic lupus erythematosus, but the optimal initial regimen is not clear. The purpose of this study was to explore the optimal initial dose of tacrolimus for children with systemic lupus erythematosus using population pharmacokinetics and pharmacogenomics. METHODS: Clinical information, tacrolimus concentrations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drugs, Chinese Herbal

Share to Immunosuppressive Agents

Share to Lupus Erythematosus, Systemic

Share to Nonlinear Dynamics

Share to Pharmacogenetics

Share to Tacrolimus

Source

Identifiers

PMID: 31755126
DOI: 10.1111/jcpt.13072

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule.PMID 31755126Read ↗

Optimization of initial dosing scheme of tacrolimus in pediatric refractory nephrotic syndrome patients based on CYP3A5 genotype and coadministration with wuzhi-capsuleSemantic proximity Read ↗

Initial dosage optimization of tacrolimus in Chinese pediatric patients undergoing kidney transplantation based on population pharmacokinetics and pharmacogenetics.Semantic proximity Read ↗

Dosing strategy of tacrolimus when co-administered with Wuzhi tablet in renal transplant recipients.Semantic proximity Read ↗

Pharmacogenomics-based tacrolimus combined with Wuzhi capsules in precision medicine in kidney transplant patientsSemantic proximity Read ↗

Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients.Semantic proximity Read ↗

Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome.Semantic proximity Read ↗

Prediction of tacrolimus and Wuzhi tablet pharmacokinetic interaction magnitude in renal transplant recipients.Semantic proximity Read ↗

Genotype Informed Bayesian Dosing of Tacrolimus in Paediatric Solid Organ Transplant IndividualsSemantic proximity Read ↗

Tacrolimus Population Pharmacokinetic Model in Chinese Patients with Nephrotic Syndrome and Dosing Regimen Identification Using Monte Carlo SimulationsSemantic proximity Read ↗

Diltiazem on tacrolimus exposure and dose sparing in Chinese pediatric primary nephrotic syndrome: impact of CYP3A4, CYP3A5, ABCB1, and SLCO1B3 polymorphisms.Semantic proximity Read ↗

Dosage optimization of tacrolimus based on the glucocorticoid dose and pharmacogenetics in adult patients with systemic lupus erythematosus.Semantic proximity Read ↗

Effects and safety evaluation of Wuzhi Capsules combined with tacrolimus for the treatment of kidney transplantation recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.